Research Article

Kailing Wang, Yong Li, Jianfeng Pan, Huifang He, Ziyi Zhao, Yiming Guo, Xiaomei Zhang*

Noninvasive diagnosis of AIH/PBC overlap syndrome based on prediction models

https://doi.org/10.1515/med-2022-0526
received January 14, 2022; accepted June 24, 2022

Abstract: Autoimmune liver diseases (AILDs) are life-threatening chronic liver diseases, mainly including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and AIH–PBC overlap syndrome (OS), which are difficult to distinguish clinically at early stages. This study aimed to establish model to achieve the purpose of the diagnosis of AIH/PBC OS in a noninvasive way. A total of 201 AILDs patients were included in this retrospective study who underwent liver biopsy during January 2011 to December 2020. Serological factors significantly associated with OS were determined by the univariate analysis. Two multivariate models based on these factors were constructed to predict the diagnosis of AIH/PBC OS using logistic regression and random forest analysis. The results showed that immunoglobulins G and M had significant importance in both models. In logistic regression model, anti-Sp100, anti-Ro-52, anti-SSA, or antinuclear antibody positivity were risk factors for OS. In random forest model, activated partial thromboplastin time and α-fetoprotein level were important. To distinguish PBC and OS, the sensitivity and specificity of logistic regression model were 0.889 and 0.727, respectively, and the sensitivity and specificity of random forest model were 0.944 and 0.818, respectively. In conclusion, we established two predictive models for the diagnosis of AIH/PBC OS in a noninvasive method and they showed better performance than Paris criteria for the definition of AIH/PBC OS.

Keywords: primary biliary cirrhosis, predictive model, immunoglobulin

1 Introduction

Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis are main categories of autoimmune liver diseases (AILDs) caused by anomalous response of immune system to self-antigens on hepatocytes or bile ducts. AIH and PBC have different mechanisms and clinical manifestations. In AIH, autoimmune injury mainly affects the hepatocytes, leading to the presence of interface hepatitis in liver histology, and AIH is characterized by high levels of immunoglobulin G (IgG) or γ-globulin and some positive serum autoantibodies [1]. PBC is characterized by circulating anti-mitochondrial antibodies (AMAs), chronic cholestasis, and autoimmunity on the intrahepatic small bile ducts, and the liver biopsy findings show typical appearance of non-purulent granulomatous destructive cholangitis [2,3]. About 2–19% of patients share overlapping features of both PBC and AIH, and it is called PBC–AIH overlap syndrome (OS) [4–7]. OS may represent an important and unrecognized cause of resistance to ursodeoxycholic acid in patients with PBC [6]. If treated inappropriate, OS leads to the development of liver cirrhosis rapidly and even liver failure, which need liver transplantation [8]. Therefore, early diagnosis and proper treatment of OS are extremely important.

The sensitivity and specificity of the Paris criteria for OS were reported to be 92 and 97%, respectively [9]. However, patients with less severe forms of AIH–PBC OS may not be captured by the Paris criteria [10]. The gold standard for diagnosing AILDs is still liver pathology, which can evaluate the severity and prognosis and determine treatment options [11,12]. However, liver biopsy has some disadvantages. First, about one quarter of patients already develop cirrhosis at diagnosis [13], have poor blood clotting and a greater risk, and increase the possibility of complications. Second, sampling process errors occur in needle liver biopsies of AILDs, which may be affected by different extents of lesions. Finally, OS should not be over-diagnosed to avoid the risk of steroid side effects on PBC patients [14,15].
Therefore, a noninvasive method as a supplementa-
tion for biopsy is urgently needed to differentiate PBC and
OS, which should be safe, convenient, accurate, and
effective. This noninvasive approach helps integrate numerous
clinical parameters, providing a reliable understanding of liver
pathology features and prognosis. The artificial intelligence
model is well suited to this challenge and has already been
used to predict effects of different treatment options [16–19].

This study aimed to develop and validate a prediction
model for predicting the diagnosis of AIH/PBC OS based
on machine learning models. We utilized the AILD patient
cohort and selected valuable parameters and weighed for
their importance.

2 Patients and methods

2.1 Patient and public involvement

It was not appropriate or possible to involve patients or
the public in the design, or conduct, or reporting, or dis-
semination plans of our research.

This study was approved by Ethics Committee of
Xiangya Hospital of Central South University (Changsha,
China, Approval ID: 20341), and all patients provided
informed consent. A total of 201 patients with AILDs
admitted to Xiangya Hospital between 2011 and 2020
were retrospectively analyzed.

Patients with AIH were selected based on the inter-
national group for the study of AIH simplified criteria
[20]. These simplified diagnostic criteria for AIH have
been validated in different countries including China
[21–23]. PBC patients were classified according to the
Paris criteria [10]. PBC–AIH OS was strictly defined by
the association of PBC and AIH either simultaneously or
consecutively [9]. In the absence of biliary obstruction
was assessed by ultrasonography and hepa-
titis virus serology, and copper blue protein was negative.
None had excessive alcohol consumption (<20 g/day),
and there was no evidence of exposure to hepatop-
orbile duct toxicity. To ensure an accurate classification
of AILDs, all patients had pathological results of liver
biopsy. Among 201 patients with AILDs, 65 patients were
excluded according to the exclusion criteria as follows: age
<18 years (n = 2), virus hepatitis (n = 52), drug-induced
liver injury (n = 3), liver cancer (n = 2), blood disease
(n = 1), and incomplete information (n = 5).

2.2 Collection of clinical and pathology data

Information on each patient, including history as well as
symptoms, clinical findings, and data from laboratory or
other diagnostic investigations were obtained, including
age and sex; clinical symptoms including pruritus, jaun-
dice, and fatigue; red blood cell (RBC), white blood cell
(WBC), platelet (PLT), lymphocyte count (L), eosinophil
count (E), basophil count (B), monocyte count (M), aspar-
tate aminotransferase (AST), alkaline phosphatase (ALP),
γ-glutamyl transferase, international normalized ratio (INR),
activated partial thromboplastin time (APTT), IgG, immuno-
globulin A (IgA), immunoglobulin M (IgM), and auto-anti-
body tests. All auto-antibody tests were performed using
Western blot-based antibody detection kits (Oumeng
Diagnostics Ltd., Germany).

2.3 Statistical analysis

Continuous variables were described as median and inter-
quartile range (IQR), and categorical variables were described
as absolute frequencies and percentages. SPSS 25.0 was uti-
lized for statistical analysis. The chi-squared test or Fischer’s
exact test was used to compare categorical data. For the para-
metric distribution, Student’s t-test was used to compare the
mean values of two groups. For nonparametric variables, the
Kruskal–Wallis test or Mann–Whitney U test was used. All P-
values were two-sided, and P-values <0.05 were considered
statistically significant.

2.4 Model establishment

A random forest model was constructed to distinguish
PBC from OS using the statistical language R (version
3.3), with the packages random forest, pROC, and rms.
The random forest creates multiple training sets for deci-
sion trees, wherein each tree is built based on a bootstrap
sample drawn randomly from the original dataset using
the classification and regression tree method and the
decrease Gini impurity as the splitting criterion [24]. Of
the final cohort included, 70% were selected for training
and the remaining for validation. A 10-fold cross-valida-
tion strategy was performed during training. In the model,
we determined 500 decision trees in the forest, and 5 vari-
ables were considered on each decision tree. The
maximum depth of the trees was set to 3 [25]. The confidence intervals for area under the receiver-operating characteristic curve (AUC) and other evaluation criteria were constructed using bootstrapping. The one that produced an AUC closest to the average was considered the best trained model. The model was then verified in the testing dataset. We selected the AUC, accuracy, sensitivity, and specificity to evaluate the performance of the model. The input variables in our model were ranked by relative importance in diagnosing PBC based on the mean decrease in accuracy and the mean decrease in the Gini coefficient [26]. Moreover, we developed the logistic regression model using the same training data and testing data.

3 Results

3.1 Demographics and baseline features

The medical records of 201 AILD patients with liver biopsy were reviewed. Finally, 136 patients were enrolled in this study and divided into the PBC group (35, 25.74%), the AIH group (44, 32.35%), and the OS group (57, 41.91%) (Figure 1). We found no difference in the distribution of age or sex among the three groups. The general characteristics of the study participants are summarized in Table 1.

3.2 Comparison between AIH and other liver diseases

To explore the difference between AIH and other ALDs, we performed single-factor and multi-factor comparisons. The blood indexes of study subjects are shown in

| Variables                | AIH (N = 44) | PBC (N = 35) | OS (N = 57) | P*-value |
|-------------------------|--------------|--------------|-------------|----------|
| Female                  | 41 (93.2%)   | 27 (77.1%)   | 48 (84.2%)  | 0.129    |
| Age, years              | 51.3 (10.1)  | 47.5 (12.0)  | 50.1 (9.6)  | 0.504    |
| Jaundice                | 23 (52.3%)   | 22 (62.9%)   | 37 (64.9%)  | 0.406    |
| Pruritus                | 0 (0%)       | 5 (14.3%)    | 7 (12.3%)   | 0.04     |
| Fatigue                 | 12 (27.3%)   | 7 (20%)      | 17 (29.8%)  | 0.584    |
| Liver palms             | 5 (11.4%)    | 1 (2.9%)     | 9 (15.8%)   | 0.154    |
| Spider angioma          | 4 (9.8%)     | 1 (2.9%)     | 7 (12.3%)   | 0.273    |
| Lower limb edema        | 5 (11.4%)    | 6 (14.6%)    | 4 (7.0%)    | 0.325    |
| Hepatomegaly            | 5 (11.4%)    | 6 (14.6%)    | 13 (22.8%)  | 0.319    |
| Splenomegaly            | 20 (48.8%)   | 17 (48.6%)   | 45 (79.0%)  | 0.001    |
| Ascites                 | 10 (24.4%)   | 13 (31.7%)   | 12 (21.1%)  | 0.218    |
| Other AIDs              | 8 (18.2%)    | 8 (22.9%)    | 14 (24.6%)  | 0.753    |
| Gallbladder diseases    | 22 (50.0%)   | 14 (40.0%)   | 21 (36.8%)  | 0.412    |
| Liver cirrhosis         | 17 (38.6%)   | 12 (34.3%)   | 33 (57.9%)  | 0.045    |
| Varicose veins          | 4 (9.1%)     | 4 (11.4%)    | 15 (26.3%)  | 0.046    |
| Infection               | 7 (15.9%)    | 6 (17.1%)    | 10 (17.5%)  | 0.976    |

Data are median (IQR) or n (%). A P-value of less than 0.05 is considered statistically significant among three groups.

*The P-value represents comparison between AIH, PBC, and OS within the test panel.
Table 2: Blood indexes of patients studied

| Parameters                  | AIH  (N = 44) | PBC  (N = 35) | OS   (N = 57) | P*-value |
|-----------------------------|---------------|---------------|---------------|----------|
| WBC (109/L)                 | 4.65 (1.67)   | 5.1 (2.3)     | 4.4 (2.4)     | 0.621    |
| RBC (1,012/L)               | 4.07 (0.82)   | 3.9 (1.13)    | 3.7 (0.6)     | 0.114    |
| Hb (g/L)                    | 122.5 (33.5)  | 115.0 (32.0)  | 113 (28.5)    | 0.522    |
| PLT (109/L)                 | 161 (118.75)  | 166 (108.0)   | 166 (105.5)   | 0.727    |
| N (109/L)                   | 2.7 (1.13)    | 3 (2)         | 2.7 (1.5)     | 0.392    |
| L (109/L)                   | 1.3 (0.8)     | 2.3 (1.6)     | 1.78 (1.2)    | <0.001   |
| E (109/L)                   | 0.1 (1.18)    | 1.4 (0.8)     | 1.5 (0.7)     | <0.001   |
| B (109/L)                   | 0 (0)         | 0.1 (0.1)     | 0.1 (0.19)    | <0.001   |
| M (109/L)                   | 0.55 (0.3)    | 0.07 (0.10)   | 0.08 (0.11)   | <0.001   |
| NLR (%)                     | 178.63 (95.98)| 231.82 (150)  | 178.26 (116.57)| 0.337    |
| ELR (%)                     | 5 (11.11)     | 6.25 (10)     | 8 (10.55)     | 0.353    |
| BLR (%)                     | 0 (0)         | 0 (0)         | 0 (1.52)      | 0.42     |
| MLR (%)                     | 39.23 (27.74) | 27.78 (21.43) | 27.27 (0.213) | 0.008    |
| Albumin (g/L)               | 0.88 (0.54)   | 0.82 (0.58)   | 0.91 (0.46)   | 0.451    |
| Globulin (g/L)              | 35.5 (9.83)   | 38.2 (9.3)    | 38.5 (7.65)   | 0.066    |
| TBIL (mol/L)                | 38.65 (10.68) | 34.6 (10.3)   | 43.8 (8.35)   | <0.001   |
| DBIL (mol/L)                | 40.3 (84.68)  | 31.9 (54.6)   | 39.2 (50.1)   | 0.357    |
| Bile acid (mol/L)           | 24.25 (46.88) | 19.8 (36.1)   | 20.4 (30)     | 0.467    |
| ALP (U/L)                   | 3.05 (1.12)   | 3.05 (1.12)   | 3.05 (1.12)   | <0.001   |
| AST (U/L)                   | 127.85 (322.55)| 87.9 (121.8)  | 95.3 (96.65)  | 0.078    |
| AAR (%)                     | 159.15 (327.58)| 96 (95.99)    | 133.5 (102.75)| 0.042    |
| ALP (U/L)                   | 129.74 (82.75)| 120.19 (88.1)| 139.41 (71.73)| 0.487    |
| γ-GT (U/L)                  | 164.75 (167.85)| 443 (430.3)   | 367.4 (518.3) | <0.001   |
| 5-Nucleotidase (U/L)        | 151.8 (141.29)| 381 (592.4)   | 348.8 (425.1) | <0.001   |
| Fucosidase (U/L)            | 10.75 (14.65) | 36.9 (95.7)   | 51.9 (69.1)   | <0.001   |
| mAST (U/L)                  | 37.25 (16.82) | 42.5 (25.8)   | 41.7 (27.35)  | 0.532    |
| Triglycerides (mmol/L)      | 29.55 (40.64) | 27.5 (30.4)   | 34.8 (24.8)   | 0.375    |
| Cholesterol (mmol/L)        | 1.54 (0.82)   | 2.1 (0.98)    | 1.7 (0.89)    | 0.02     |
| HDL (mmol/L)                | 4.16 (1.48)   | 6.4 (3.84)    | 6.07 (2.39)   | <0.001   |
| LDL (mmol/L)                | 1.005 (0.66)  | 1.56 (0.97)   | 1.63 (0.9)    | <0.001   |
| PT (s)                      | 2.38 (0.86)   | 4.1 (2.1)     | 3.51 (1.46)   | <0.001   |
| INR                          | 14.4 (3.25)   | 12.7 (1.6)    | 13.3 (2.25)   | <0.001   |
| APTT (s)                    | 1.13 (0.27)   | 0.99 (0.14)   | 1.05 (0.16)   | <0.001   |
| Fibrinogen (g/L)            | 40.27 (7.1)   | 33.9 (9.0)    | 38.16 (7.8)   | 0.002    |
| D-dimer (mg/L)              | 2.22 (0.92)   | 3.15 (1.27)   | 2.9 (1.01)    | <0.001   |
| K (mmol/L)                  | 0.25 (0.15)   | 0.16 (0.22)   | 0.18 (0.16)   | 0.238    |
| Na (mmol/L)                 | 3.72 (0.7)    | 3.86 (0.42)   | 3.74 (0.41)   | 0.217    |
| Cl (mmol/L)                 | 139.85 (3.05) | 141.55 (3)    | 140.3 (4.6)   | 0.221    |
| Ca (mmol/L)                 | 104.17 (3.08) | 104.27 (5)    | 103.7 (4.8)   | 0.621    |
| P (mmol/L)                  | 2.22 (0.15)   | 2.29 (0.2)    | 2.23 (0.16)   | 0.027    |
| Mg (mmol/L)                 | 1.12 (0.24)   | 1.17 (0.25)   | 1.12 (0.21)   | 0.373    |
| C3 (mg/L)                   | 0.84 (0.09)   | 0.84 (0.11)   | 0.84 (0.08)   | 0.881    |
| C4 (mg/L)                   | 152 (75.5)    | 194 (118)     | 192 (79)      | 0.012    |
| IgG (g/L)                   | 846.5 (346.5) | 1,130 (566)   | 1,030 (335.5) | <0.001   |
| IgA (mg/L)                  | 22.25 (10.55) | 2695.52 (1,840)| 3740 (2,060)| 0.002    |
| IgM (mg/L)                  | 3,220 (2,265) | 2,430 (2,220) | 3,950 (2,635)| <0.001   |

Data are median (IQR). Hb, hemoglobin count; N, neutrophil count; NLR, neutrophil lymphocyte ratio; ELR, eosinophil lymphocyte ratio; BLR, basophil lymphocyte ratio; MLR, monocyte lymphocyte ratio; LPR, lymphocyte platelet ratio; TBIL, total bilirubin; DBIL, direct bilirubin; AAR, AST and ALT ratio; γ-GT, γ-glutamyl transferase; mAST, mitochondrial aspartate aminotransferase; C4, complement C4; C3, complement C3.

*A P-value of less than 0.05 is considered statistically significant.
Table 3: Comparison between PBC and OS

| Parameters  | PBC (n = 35) | OS (n = 57) | P-value |
|-------------|--------------|-------------|---------|
| Sp100 (n, %)| 4 (11.43%)   | 17 (29.82%) | 0.041   |
| RO-52 (n, %)| 10 (28.57%)  | 32 (56.14%) | 0.010   |
| SSA (n, %)  | 2 (5.71%)    | 19 (33.33%) | 0.002   |
| ANA (n, %)  | 7 (20.00%)   | 0 (0.00%)   | 0.006   |
| Globulin (g/L)| 34.6 (10.3) | 43.8 (8.35) |         |
| IgG (g/L)   | 14.3 (4.9)   | 22.4 (6.4)  |         |
| IgA (mg/L)  | 2695.52 (1840)| 3740 (2060)|         |
| IgM (mg/L)  | 2430 (2220)  | 3950 (2635) |         |

A P-value of less than 0.05 is considered statistically significant.

Table 2. In immunological index, more AIHs were positive for antibodies against M2-3E (BPO), while more PBC and OS were positive for AMA, and antinuclear antibody (ANA) showed significant differences. Sjogren's syndrome (SS)-related SSA was associated with PBC [odds ratio (OR) 5.5, P = 0.02]. RO-52 was associated with OS (OR 0.26, P = 0.002).

We put the variables with P-values less than 0.05 in the univariate analysis into the logistic regression analysis. The AUC between AIH and PBC and between AIH and OS was 1.

Comparison between PBC and OS showed that Sp100, RO-52, and SSA were associated with OS: Sp100 (OR 95% CI: 0.30 [0.09–0.99], P = 0.041), RO-52 (OR 95% CI: 0.313 [0.13–0.77], P = 0.01), and SSA (OR 95% CI: 0.12 [0.03–0.56], P = 0.002) (Table 3).

3.3 Construction of model to discriminate PBC and OS

To construct prediction model to discriminate PBC and OS, first we ranked the variables used to construct the model in the order of importance (Figure 2a). For the model based on random forest after over 50 replications, we chose a model which displayed the receiver-operating characteristic (ROC) under the selected training and testing cohort with the AUC of 0.93 (95% CI: 0.91–0.99), the closest to the average. According to the mean decrease in the Gini value, we found that the five strongest predictor variables used to differentiate PBC from OS were α-fetoprotein (AFP), APTT, globulin (GLB), IgG, and IgM (Figure 2b). After validation in the remaining 30% of samples, the random forest model could predict the outcome with the sensitivity of 0.944 and the specificity of 0.818. The effects of these five variables on the outcome of diagnosing PBC are shown in Figure 3.

We also established prediction model applying binary logistic regression algorithms with the sensitivity of 0.889 and the specificity of 0.727 after testing in the same data. The AUC for this model was 0.78 (95% CI: 0.63–0.86), which was lower than that of the random forest model (Figure 4).

4 Discussion

In this retrospective study, we conducted single-factor and multi-factor analysis of patients with AILDs. When AIH was compared with PBC and OS, many variables showed significant differences, indicating that it is easy to distinguish them. However, it is difficult to distinguish PBC from OS, because the two diseases lack unique clinical characteristics [6]. In fact, there is no international consensus on the definition of OS in daily practice, especially on the histological level. The percentage of OS patients was higher than usual, which may be related to the fact that liver biopsy is not necessary for the diagnosis of PBC alone [11]. Moreover, we excluded some patients with comorbidities, which may have some selection bias. For AIH and OS, liver biopsy is necessary, and the early detection rate of OS patients has increased because of liver biopsy [12]. Therefore, we established two prediction models to reduce unnecessary operations and make effective early diagnosis. The results showed that the models had powerful competence to differentiate PBC and OS.

In our study, it is important to note that the magnitude of elevated IgG in OS was more than that in PBC. From a clinical point of view, hypergammaglobulinemia is one of the prominent clinical characteristics of AIH patients, and the decrease in IgG is an important aspect for disease control [27]. The presence of a combination of
anti-double-stranded DNA (anti-dsDNA), elevated alanine aminotransferase (ALT), and elevated IgG levels should prompt a clinician to a potential diagnosis of OS [28]. We found similar result that OS is more prone to higher levels of immunoglobulins, IgG and IgM, in random forest model. Many autoantibodies have been detected in AILDs, and AMA has been recognized as specific targets of PBC [29]. However, in our study, we found no difference in AMA between PBC and OS, which may be related to the fact that OS has clinical traits of PBC. AMAs are not associated with disease progression, while ANAs are related to disease severity and clinical outcome, and are the markers of poor prognosis. In particular, ANAs are detected in up to 50% PBC patients. Two immunofluorescence patterns are considered PBC specific: the multiple nuclear dot patterns for antigens, such as Sp100 and promyelocytic leukemia protein, and rim-like/membranous patterns for antigens, such as gp210, nucleoporin p62, and the lamin B receptor [30,31]. In our study, the prevalence of ANA was 100% in AIH and 80% in PBC patients.

It was reported that sp100 had a sensitivity of 40% and a specificity of 97.3% for PBC [32]. OS also has the characteristics of PBC, and Sp100 and SSA may be

---

**Figure 2:** The importance ranking of variables predicting the diagnosis of PBC and OS. (a) OS-related variables ranked by logistic regression analysis ($P < 0.05$). (b) OS-related variables ranked by random forest analysis. SSA, anti-SSA antibody; Sp100, anti-Sp100 antibody; P, serum phosphorus level; K, serum potassium level; TG, triglyceride; C4, complement 4; BA, serum bile acid; DB, direct bilirubin; TB, total bilirubin; FIB, fibrin; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
potential autoantibodies to differentiate patients between PBC and OS. In fact, SSA and anticentromere antibody (ACA) are helpful for the diagnosis of PBC with SS, and SSA and ACA are recognized as serological markers of AMA negative PBC patients [33]. In our study, OS patients were more likely to have SS. Anti-dsDNA and anti-p53 have been suggested to be potential autoantibodies for identifying patients with OS [27, 34].

Furthermore, gp210 antibodies in PBC are associated with severe prognosis [35]. One study found significantly higher frequency of anti-gp210 in patients with OS than in patients with PBC [36], indicating that OS has a worse prognosis. However, we did not detect significantly higher frequencies of gp210, dsDNA, and p53 in OS patients compared to PBC patients.

Logistic regression model showed that the combination of splenomegaly with Sp100, SSA, and IgG levels was able to differentiate patients with OS from those with PBC. In random forest model, APTT and AFP level were factors in the top 5. It has been reported that prothrombin time (PT) and APTT can be used as appropriate predictors for decision-making. Figure 3: The effects of five important variables on the outcome of diagnosing OS. (a) GLB. (b) IgG. (c) IgM. (d) APTT. (e) AFP.

Figure 4: The ROC curve of predictive models for distinguish PBC with OS. RF, random forest; LR, logistic regression.
of bleeding risk due to impaired liver synthesis and reduced procoagulant factors in cirrhosis [37]. However, other study showed that APTT abnormalities were poorly associated with bleeding [38]. Therefore, the importance of APTT is controversial and requires follow-up verification. Generally, the sensitivity and specificity of random forest model were better than those of logistic regression model, which is likely due to the strong generalization power of the random forest model [39].

Recently, Wang et al. developed a nice model based on limited sociodemographic and clinical parameters from routine health checkup to identify individuals at high risk for AILD [40]. In contrast, our model has unique advantages: it is noninvasive; it integrates multiple irrelevant variables simultaneously and evaluates the weight of each variable; it can be refined continuously as database enlarges and sensitive variables are constantly discovered. More importantly, our model could be used to distinguish PBC and OS. Similarly, Zhang et al. developed a scoring classification based on selected histologic features of AIH and PBC and modified biochemical and immunologic characteristics, and it showed a high sensitivity and specificity for the diagnosis of OS and may be better than current OS scoring systems to detect mild forms of OS [41].

It should be noted that our study has some limitations. First, we did not compare healthy control cohort. Second, our sample size is relatively small. Third, to improve the sensitivity and specificity of our model, we focused on the factors with importance ranking shown in Figure 1 and did not include other significant biomarkers or demographic factors, such as those used in previous study [40]. Further studies are needed to explore novel and sensitive parameters. With the enlargement of data, machine learning will gain power and become a promising approach to distinguishing PBC and OS.

In conclusion, we constructed two models with sufficient accuracy to predict the diagnosis of PBC and OS patients who probably benefit from early treatment based on readily available parameters. Following the use in clinical practice, these models help patients with early and effective treatment and reduce surveillance liver biopsies in the future.

**Funding information:** This work was supported by the Natural Science Foundation of China (No. 81873575).

**Author contributions:** Xiaomei Zhang conceived the study. Kailing Wang and Yong Li contributed to the conception and design of the study. All the authors contributed to the collection of data and the analysis and interpretation of the data. Kailing Wang and Xiaomei Zhang contributed to the drafting of the article, and the other authors contributed to the critical revision of the article for important intellectual content. Xiaomei Zhang supervised this study. All the authors approved the final draft of the article.

**Conflict of interest:** The authors declare no conflict of interest.

**Data availability statement:** All data are available upon request.

**References**

[1] Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006 Jan 5;354(1):54–66.
[2] Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7(7):926–41.
[3] Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014;60(1):210–23.
[4] Chazouillères O. Overlap syndromes. Dig Dis. 2015;33(2):181–7.
[5] European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.
[6] Chazouillères O, Wendem D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology. 1998;28(2):296–301.
[7] Boberg KM, Chapman RW, Hirschfield GM, Lohe AW, Manns MP, Schrumpl E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374–85.
[8] Pells G, Mells G, Carbone M, Newton JL, Bathgate AJ, Burroughs AK, et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol. 2013;59(1):67–73.
[9] Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8(6):530–4.
[10] European association for the study of the liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72.
[11] Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American association for the study of liver diseases. Liver biopsy. Hepatology. 2009;49(3):1017–44.
[12] Spengler U, Fischer HP. Die leberbiopsie im schnittpunkt von klinischer und pathologischer Diagnostik [Liver biopsy at the intersection of clinical and pathological diagnosis]. Pathologe. 2008;29(1):6–14.
[13] Limaye SS, Mastrangelo CM. Systems modeling approach for reducing the risk of healthcare-associated infections.
16. Chen W, Bi K, Jiang J, Zhang X, Diao H. Integrated analysis of human influenza A (H1N1) virus infection related genes to construct a suitable diagnostic model. Biocell. 2021;45(4):885–99.

17. Li J, Li H, Zeng H, Zheng R, Cao M, Sun D, et al. Trends in high-risk rates and screening rates for the population-based cancer screening program on esophageal, stomach and liver cancer in China, 2010–2016. J Natl Cancer Cent. 2021;1(3):101.

18. Waljee AK, Lipson R, Wittala WL, Zhang Y, Liu B, Zhu J, et al. Predicting hospitalization and outpatient corticosteroid use in inflammatory bowel disease patients using machine learning. Inflamm Bowel Dis. 2017;24(1):45–53.

19. Hu X, Jing FY, Wang QJ, Shi LY, Cao YF, Zhu ZT. Alteration of ornithine metabolic pathway in colon cancer and multivariate data modelling for cancer diagnosis. Oncologie. 2021;23(2):203–17.

20. Hennes EM, Zeniya M, Czaia AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76.

21. Muratori P, Granito A, Pappas G, Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology. 2009 May;49(5):1782–3.

22. Candia R, Noreno B, Águedo C, Díaz L, Ortega JP, Wolff R, et al. Validation of the simplified criteria for the diagnosis of autoimmune hepatitis in chilean-hispanic patients. Ann Hepatol. 2017;16(5):772–9.

23. Liu F, Pan ZG, Ye J, Xu D, Guo H, Li GP, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients. J Dig Dis. 2016;15(12):660–8.

24. Shkurnin A, Vellido A. Using random forests for assistance in the curation of G-protein coupled receptor databases. Biomed Eng Online. 2017;16:75.

25. Wu J, Qiu J, Xie J, Jiang W, Zhao R, Qiu J, et al. Predicting in-hospital rupture of type A aortic dissection using Random Forest. J Thorac Dis. 2019;11(11):4634–46.

26. Su X, Xu Y, Tan Z, Wang X, Yang P, Su Y, et al. Prediction for cardiovascular diseases based on laboratory data: An analysis of random forest model. J Clin Lab Anal. 2020;34(9):e23421.

27. Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104(6):1420–5.

28. Manns MP, Czaia AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. American association for the study of liver diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.

29. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World J Gastroenterol. 2010;16(29):3616–29.

30. Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, et al. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24(11–12):1575–83.

31. Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12(1):65–74.

32. Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gough P, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009;36(10):2250–6.

33. Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;26(6):831–8.

34. Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, et al. Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. Can J Gastroenterol. 2012;26(3):125–9.

35. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45(1):118–27.

36. Saito H, Takahashi A, Abe K, Okai K, Katsushima F, Monoe K, et al. Autoantibodies by line immunoassay in patients with primary biliary cirrhosis. Fukushima J Med Sci. 2012;58(2):107–16.

37. Tripodi A. Liver Disease and Hemostatic (Dys)function. Semin Thromb Hemost. 2015;41(5):462–7.

38. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56.

39. Xiao Y, Zhou P, Zheng YZ, Zheng C, Liu GW, Liu WX. A nomogram for predicting lateral lymph node metastasis in cases of papillary thyroid micro-carcinoma with suspected lymph node metastasis. Oncologie. 2021;23(2):219–28.

40. Wang Y, Li Y, Wang X, Gacesa R, Zhang J, Zhou L, et al. Predicting liver disease risk using a combination of common clinical markers: a screening model from routine health check-up. Dis Markers. 2020;2020:8460883.

41. Zhang W, De D, Mohammed KA, Munigala S, Chen G, Lai JP, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun. 2018;2(3):245–53.